International consensus guidelines for advanced breast cancer ( ABC 1 )

The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon. Consensus guidelines for the management of this disease were developed. This manuscript summarizes these international consensus guidelines. 2012 Published by Elsevier Ltd. Coordinator, Director Breast rasília e Doca de Pedrouços, maud.pt (F. Cardoso).

[1]  N. Houssami,et al.  Imaging bone metastases in breast cancer: evidence on comparative test accuracy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[3]  M. Pegram,et al.  Trastuzumab treatment in multiple lines: current data and future directions. , 2012, Clinical breast cancer.

[4]  M. Mouret-Reynier,et al.  Late lines of treatment benefit survival in metastatic breast cancer in current practice? , 2011, Breast.

[5]  Val Gebski,et al.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Gnant,et al.  Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Jonathan White,et al.  Male breast carcinoma: increased awareness needed , 2011, Breast Cancer Research.

[8]  M. Ernst,et al.  The role of surgery in metastatic breast cancer. , 2011, European journal of cancer.

[9]  H. Malhotra,et al.  Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer , 2011 .

[10]  P. Selby,et al.  Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Niland,et al.  Surgery of the primary tumor does not improve survival in stage IV breast cancer , 2011, Breast Cancer Research and Treatment.

[12]  K. Foley.  How well is cancer pain treated? , 2011, Palliative medicine.

[13]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Mauro D'Amico,et al.  Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Bergh,et al.  Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden , 2011, Breast Cancer Research and Treatment.

[16]  Tarek Mekhail,et al.  Adjuvant Whole-Brain Radiotherapy Versus Observation after Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study , 2011, Current oncology reports.

[17]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Adebamowo,et al.  Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. , 2011, The Lancet. Oncology.

[19]  Marilys Corbex,et al.  Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. , 2011, Breast.

[20]  J. V. Von Roenn,et al.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Chris Twelves,et al.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study , 2011, The Lancet.

[22]  A. Day,et al.  Trends in Survival After Surgery for Breast Cancer Metastatic to the Brain and Spinal Column in Medicare Patients: A Population-Based Analysis , 2011, Neurosurgery.

[23]  D. Kondziolka,et al.  Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. , 2011, Journal of neurosurgery.

[24]  B. Kiely,et al.  How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[27]  T. Delozier,et al.  Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). , 2010 .

[28]  M. Hatano,et al.  Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional prospective study. , 2010, Journal of neurosurgery.

[29]  M. Craike,et al.  Does multidisciplinary care enhance the management of advanced breast cancer?: evaluation of advanced breast cancer multidisciplinary team meetings. , 2010, Journal of oncology practice.

[30]  G. Vlastos,et al.  Local-Regional Radiotherapy and Surgery is Associated with a Significant Survival Advantage in Metastatic Breast Cancer Patients , 2010, Tumori.

[31]  Theodoros N. Arvanitis,et al.  A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. , 2010, Health technology assessment.

[32]  Robert Kevin Grigsby,et al.  ABC conceptual model of effective multidisciplinary cancer care , 2010, Nature Reviews Clinical Oncology.

[33]  Alona Muzikansky,et al.  Early palliative care for patients with metastatic non-small-cell lung cancer. , 2010, The New England journal of medicine.

[34]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J. Bergh,et al.  Multidisciplinary meeting on male breast cancer: summary and research recommendations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  V. Speirs,et al.  Problems (and solutions) in the study of male breast cancer , 2010, Rare tumors.

[38]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Younus,et al.  Management of hot flashes in women with breast cancer , 2010, Current oncology.

[40]  Kristine R Broglio,et al.  Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.

[41]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[44]  F. Cardoso.  Metastatic breast cancer patients: the forgotten heroes! , 2009, Breast.

[45]  E. Winer,et al.  International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy , 2009, Journal of the National Cancer Institute.

[46]  Jingfei Ma,et al.  Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. , 2009, The Lancet. Oncology.

[47]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H. Gómez,et al.  Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Dear,et al.  Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. , 2008, European journal of cancer.

[50]  J. Niland,et al.  Selecting High Priority Quality Measures For Breast Cancer Quality Improvement , 2008, Medical care.

[51]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Tomasz Burzykowski,et al.  Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[54]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[55]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  S. Johnston,et al.  Factors determining outcome after third line chemotherapy for metastatic breast cancer. , 2007, Breast.

[57]  A. Chacko,et al.  Interventions for the treatment of metastatic extradural spinal cord compression in adults. , 2008, The Cochrane database of systematic reviews.

[58]  J. Griggs,et al.  Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  E. Winer,et al.  Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. , 2007, Breast.

[60]  G. Hortobagyi,et al.  Leuprolide acetate plus aromatase inhibition for male breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[62]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  C. I. Adams,et al.  Metastatic spinal cord syndromes: imaging appearances and treatment planning. , 2005, Clinical radiology.

[64]  Helen Swede,et al.  Epidemiology of male breast cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[65]  M. Rivard,et al.  Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Rouzier,et al.  Breast cancer with synchronous metastases: trends in survival during a 14-year period. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[68]  A. Young,et al.  Metastatic spinal cord compression: a randomized trial of direct decompressive surgical resection plus radiotherapy vs. radiotherapy alone , 2003 .

[69]  D. Ghersi,et al.  Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.

[70]  R. Mariani-Costantini,et al.  BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. , 2003, Cancer research.

[71]  L. Fallowfield.  Quality of life: a new perspective for cancer patients , 2002, Nature Reviews Cancer.

[72]  G. Hortobagyi,et al.  Efficacy of Anastrozole in Male Breast Cancer , 2002, American journal of clinical oncology.

[73]  M. Piccart,et al.  Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  A. Evans,et al.  Imaging of metastatic breast cancer: distribution and radiological assessment at presentation. , 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

[75]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[76]  Eusoma.  The requirements of a specialist breast unit. , 2000, European journal of cancer.

[77]  A. Evans,et al.  Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. , 2000, Clinical radiology.

[78]  R. Sharpe,et al.  Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. , 2000, The Journal of endocrinology.

[79]  N. Mauras,et al.  Estrogen Suppression in Males: Metabolic Effects , 1999, The Journal of clinical endocrinology and metabolism.

[80]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[81]  C. Cuénod,et al.  Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images. , 1996, Radiology.

[82]  H. Rosenthal,et al.  Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Bhatnagar,et al.  Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. , 1993, The Journal of clinical endocrinology and metabolism.

[84]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[85]  W T Yuh,et al.  Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. , 1989, Radiology.

[86]  R. Tadmor,et al.  Early MR Demonstration of Spinal Metastases in Patients with Normal Radiographs and CT and Radionuclide Bone Scans , 1989, Journal of computer assisted tomography.

[87]  W. Smoker,et al.  Use of magnetic resonance imaging in the evaluation of metastatic spinal disease. , 1987, Neurosurgery.

[88]  F. Sim,et al.  Bone tumors: magnetic resonance imaging versus computed tomography. , 1985, Radiology.

[89]  E. Bastiaannet,et al.  Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[90]  R. Gelber,et al.  Lapatinib with trastuzumab for HER 2-positive early breast cancer ( NeoALTTO ) : a randomised , open-label , multicentre , phase 3 trial , 2012 .

[91]  M. Stockler,et al.  Bisphosphonates and other bone agents for breast cancer. , 2012, The Cochrane database of systematic reviews.

[92]  N. Kearney,et al.  2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. , 2011, European journal of cancer.

[93]  S. Khan.  Stage IV Breast Cancer in the Era of Targeted Therapy: Does Surgery of the Primary Tumor Matter? , 2011 .

[94]  R. Largillier,et al.  Aromatase inhibition in male breast cancer patients: Biological and clinical implications. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  M. Namer,et al.  Prognostic factors in 1038 women with metastatic breast cancer , 2008 .

[97]  K. Foley,et al.  Pain Control for People with Cancer and AIDS , 2006 .

[98]  G. Guyatt,et al.  Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.

[99]  D. Ghersi,et al.  Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. , 2006, The Cochrane database of systematic reviews.

[100]  T. McCauley,et al.  Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR imaging. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[101]  R. Moore,et al.  Radiotherapy for the palliation of painful bone metastases. , 2000, The Cochrane database of systematic reviews.

[102]  D. Cosgrove.  The breast , 1999, European Radiology.

[103]  E. Noordijk,et al.  The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. , 1994, International journal of radiation oncology, biology, physics.